جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

58 مُخرَج نتائج البحث عن «Randomized controlled trial»

مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Therapeutic Efficacy and Safety of Botulinum Toxin Type A in Erythematotelangiectatic Rosacea: A Systematic Review

Cureus · مجلد 18 (4) · e106841-e106841

Botulinum toxin type A (BoNT-A) injections have a well-known cosmetic outcome and safety profile in a variety of medical conditions. Recent studies have shown promising results for possible use in treating erythematotelangiectatic rosacea (ETR). This systematic review aimed to evaluate the efficacy and safety of BoNT-A injections in patients with ETR. A systematic search was conducted across multiple databases to identify relevant studies. Eligible articles were randomized controlled trials (RCTs) that investigated BoNT-A injections in adults diagnosed with ETR. Studies involving other rosacea subtypes, lacking a comparative group, or combining BoNT-A with other interventions without isolating its effects were excluded. Three RCTs met the inclusion criteria. Both parallel-group and split-face analyses demonstrated that BoNT-A injections significantly reduced facial erythema and flushing, resulting in improved patient satisfaction. Across all studies, BoNT-A was well-tolerated, with adverse events being mild, transient, and self-limited. However, the evidence remains limited by the small sample sizes, suboptimal study designs, and short follow-up durations. BoNT-A injections show promising efficacy and safety in the treatment of ETR. However, larger, well-designed randomized trials with longer follow-up durations are required to confirm its therapeutic role and establish standardized treatment protocols.

botulinum toxin type Aerythematotelangiectatic rosaceafacial erythemaflushing
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (3) · e106154-e106154

Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.

melasmalaser therapyQ-switched Nd:YAG laserpicosecond laser
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (2) · e103029-e103029

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.

ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Efficacy of Selective Serotonin Reuptake Inhibitors for the Treatment of Chronic Pain and Comorbid Depression in Individuals With Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (2) · e102998-e102998

Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.

fibromyalgiaselective serotonin reuptake inhibitorscomorbid depressionchronic widespread pain
مراجعةوصول مفتوح2026

Evaluating the therapeutic benefit of bacterial lysates in chronic obstructive pulmonary disease: a systematic review and meta-analysis

Frontiers in Medicine · مجلد 13

Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.

chronic obstructive pulmonary diseasebacterial extractsCOPD exacerbationshospitalization
مراجعةمفتوح (مستودع)2026

Comparative Efficacy and Safety of Intranasal Opioids versus Intravenous Morphine for Acute Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Emergency Medicine

Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.

intravenous morphineanalgesic efficacyadverse eventsrescue analgesia
مراجعةوصول مفتوح2026

Rifaximin Versus Placebo for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (9) · e116820-e116820

Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.

rifaximinirritable bowel syndromeplacebo comparisonantibiotic therapy
مراجعةوصول مفتوح2026

Post-acne Erythema: A Systematic Review of Randomized Controlled Trials on the Comparative Efficacy and Safety of Interventions Across Clinical, Instrumental, and Patient-Reported Outcomes

Cureus · مجلد 18 (9) · e116495-e116495

Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.

intense pulsed lightNd:YAG laserisotretinoinbrimonidine
مراجعةوصول مفتوح2026

Comparative Efficacy and Safety of Non-Cryotherapy Treatments Versus Cryotherapy for Plantar Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine · مجلد 15 (18) · 7071-7071

Background/Objectives: To systematically evaluate and compare the clinical efficacy and safety of non-cryotherapy modalities versus standard liquid nitrogen cryotherapy for the treatment of plantar warts, while exploring the influence of specific cryotherapy procedural parameters and intervention-related subgroup characteristics on treatment outcomes. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA guidelines. We searched four major databases from inception until 1 July 2026. The primary outcome was complete clearance. Secondary outcomes included partial clearance, recurrence, and treatment-related adverse events. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirty-one RCTs involving 2313 patients were included. No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy in complete clearance rates (RR = 1.09, 95% CI: 0.98–1.20; p = 0.10; I2 = 0.00%) or recurrence outcomes (RR = 0.90, 95% CI: 0.56–1.44; p = 0.66). Partial clearance significantly favored cryotherapy (RR = 0.65, 95% CI: 0.44–0.95; p = 0.03), particularly in subgroup analyses using two freeze–thaw cycles and treatment intervals of every two weeks. Regarding safety, topical therapies demonstrated significantly lower erythema rates than cryotherapy, while no statistically significant differences were observed in blistering, scarring, or secondary bacterial infection. Conclusions: No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy regarding complete clearance or recurrence of plantar warts. Cryotherapy may offer better partial clearance under optimized treatment parameters, whereas topical therapies may be better tolerated in selected patients.

plantar wartscryotherapyliquid nitrogentopical treatment
مراجعةوصول مفتوح2026

Oteseconazole for acute and recurrent vulvovaginal candidiasis: A systematic review, meta-analysis, and trial sequential analysis of randomized trials

Journal of International Medical Research · مجلد 54 (9) · 3000605261476919-3000605261476919

ObjectivesVulvovaginal candidiasis and its recurrent vulvovaginal candidiasis form place a significant burden on women worldwide. However, treatment options remain limited. Oteseconazole, a first-in-class tetrazole CYP51 inhibitor that received Food and Drug Administration approval for recurrent vulvovaginal candidiasis in 2022, has not yet had its comparative efficacy against fluconazole in acute vulvovaginal candidiasis systematically synthesized. In addition, the full scope of evidence for its maintenance use has not been formally synthesized. Using a dual-Population-Intervention-Comparator-Outcome (PICO) framework, this systematic review and meta-analysis aimed to: (a) evaluate whether oteseconazole provides superior efficacy to fluconazole in acute vulvovaginal candidiasis; (b) comprehensively synthesize maintenance efficacy and safety outcomes in recurrent vulvovaginal candidiasis; and (c) assess the certainty and sufficiency of the available evidence using Grading of Recommendations Assessment, Development, and Evaluation and trial sequential analysis.MethodsThis systematic review and meta-analysis was prospectively registered with PROSPERO (registration number: CRD420261331936). A systematic search of PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov was conducted without date or language restrictions. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Meta-analyses were performed using random-effects models with restricted maximum likelihood estimation and Hartung-Knapp-Sidik-Jonkman correction.ResultsA total of five unique randomized controlled trials (six PICO-level inclusions) were included, enrolling 596 participants across PICO 1 and 1090 across PICO 2. In acute vulvovaginal candidiasis (PICO 1, two trials, n = 361), oteseconazole was associated with a significantly higher therapeutic cure rate (composite clinical and mycological cure) at day 28 than fluconazole (risk ratio = 1.39, 95% confidence interval: 1.13 to 1.71; p = 0.002). Significant improvements were also observed in clinical cure at day 28 (risk ratio = 1.28, 95% confidence interval: 1.09 to 1.51; p = 0.003) and mycological cure at both day 14 (risk ratio = 1.24, 95% confidence interval: 1.09 to 1.41; p = 0.001) and day 28 (risk ratio = 1.38, 95% confidence interval: 1.20 to 1.58; p < 0.001). In recurrent vulvovaginal candidiasis prevention (PICO 2, four trials, n = 959), oteseconazole significantly reduced culture-confirmed recurrence at weeks 48-50 (risk ratio = 0.13, 95% confidence interval: 0.09 to 0.19) and week 24 (risk ratio = 0.10, 95% confidence interval: 0.07 to 0.15) and substantially prolonged the time to first recurrence (hazard ratio = 0.09, 95% confidence interval: 0.05 to 0.14), all with zero heterogeneity. Furthermore, trial sequential analysis confirmed that the cumulative evidence surpassed the required information size for both recurrence time points. Safety outcomes were comparable between groups in both settings.ConclusionsIn patients with recurrent vulvovaginal candidiasis, oteseconazole demonstrated favorable outcomes by significantly reducing recurrent infections while maintaining a comparable safety profile, supporting its use as a maintenance regimen. However, the evidence supporting its role in acute vulvovaginal candidiasis remains limited.

oteseconazolerecurrent vulvovaginal candidiasisfluconazoleCYP51 inhibitors
مراجعةوصول مفتوح2026

Neuromuscular Electrical Stimulation for Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials Evaluating Pain, Disability, Muscle Strength, and Functional Performance

Orthopedic Reviews · مجلد 18 · 168252-168252

Background: Neuromuscular electrical stimulation (NMES) is widely used in the rehabilitation of knee osteoarthritis (KOA) to improve quadriceps activation and counteract arthrogenic muscle inhibition. However, randomized controlled trials (RCTs) have reported inconsistent findings, and the overall clinical effectiveness of NMES across key patient outcomes remains uncertain. Objective: To evaluate the effects of NMES, administered alone or in combination with exercise, on pain, self-reported disability, quadriceps muscle strength, and functional performance in adults with KOA, and to explore whether treatment effects differ according to comparator intervention. Methods: A systematic review and meta-analysis of RCTs was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Scopus, Web of Science, and CENTRAL were searched from inception to April 20, 2026. Random-effects meta-analyses were performed using restricted maximum likelihood estimation. Prespecified subgroup and sensitivity analyses were undertaken, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Eight unique RCTs (10 publications) were included. Overall, NMES did not significantly improve pain, self-reported disability, quadriceps strength, or six-minute walk distance compared with pooled comparator interventions. A significant improvement was observed for Timed Up and Go performance, although this estimate was largely driven by a single trial. Prespecified subgroup analyses demonstrated that treatment effects differed according to comparator intervention. NMES combined with exercise resulted in greater pain reduction than exercise alone, whereas no consistent advantage was observed when NMES was compared with alternative conservative interventions. Most trials were judged to have low risk of bias or some concerns. Conclusions: NMES does not appear to provide consistent clinical benefits across all rehabilitation settings for KOA. Rather, its effectiveness depends on the therapeutic context in which it is delivered, with the greatest benefit observed when used as an adjunct to structured exercise rather than as a stand-alone intervention. Larger, methodologically rigorous RCTs using standardized stimulation protocols are required to define the patients most likely to benefit.

neuromuscular electrical stimulationknee osteoarthritisquadriceps strengtharthrogenic muscle inhibition
مراجعةوصول مفتوح2026

Comparative Effectiveness of Nonoperative Treatments for Acute Anterior Epistaxis in Emergency and Otolaryngology Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (8) · e115154-e115154

Acute anterior epistaxis is frequently managed with multiple nonoperative interventions, but comparative evidence regarding their effectiveness remains uncertain. This systematic review and meta-analysis evaluated the effectiveness and safety of nonoperative treatments for acute anterior epistaxis in emergency and otolaryngology settings. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through 3 July 2026 for randomized controlled trials (RCTs) comparing nonoperative hemostatic interventions in adults with acute anterior epistaxis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and random-effects meta-analysis was performed when sufficient clinical comparability was present. Nine RCTs including 1,124 participants were identified, with three trials contributing to quantitative synthesis. Topical tranexamic acid reduced rebleeding within 24 hours compared with matched vehicle controls (RR, 0.39; 95% CI, 0.17-0.89), with an absolute risk reduction of 19.1 percentage points. However, topical tranexamic acid was not associated with a significant reduction in further hemostatic intervention (RR, 0.59; 95% CI, 0.22-1.59). Other nonoperative strategies showed variable effects across heterogeneous outcomes. Overall, topical tranexamic acid may reduce early rebleeding in acute anterior epistaxis, but evidence regarding broader clinical outcomes remains limited by the small number of comparable trials, heterogeneous protocols, and inconsistent outcome definitions. Further high-quality randomized trials with standardized outcomes are required to clarify the optimal role of these interventions.

conservative treatmentepistaxis managementemergency department careotolaryngology practice
مراجعةوصول مفتوح2026

Comparison Between High-Flow Nasal Cannula (HFNC) Therapy and Noninvasive Ventilation (NIV) in Children With Bronchiolitis-Associated Acute Respiratory Failure: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (8) · e114308-e114308

The optimal noninvasive respiratory support for infants and children with severe viral bronchiolitis remains unclear. While continuous positive airway pressure (CPAP) has traditionally been considered the gold standard, high-flow nasal cannula (HFNC) therapy is a better-tolerated alternative. This systematic review and meta-analysis aimed to evaluate the comparative efficacy and safety of HFNC versus noninvasive ventilation (NIV) in pediatric patients with bronchiolitis-associated acute respiratory failure. We searched major electronic databases through June 2026. We included randomized controlled trials (RCTs) and observational cohorts comparing HFNC with NIV (CPAP/bilevel positive airway pressure (BiPAP)). The primary outcomes were treatment failure, as defined by the individual studies, and endotracheal intubation. Data were synthesized using random-effects models, and heterogeneity was explored via subgroup analysis and meta-regression. Eleven studies (seven RCTs and four observational studies) comprising 7,574 patients were included. There was no statistically significant difference in the overall risk of treatment failure between HFNC and NIV (RR 1.99, 95% CI 0.65-6.10); however, study design was a significant moderator (p = 0.0019). Observational studies reported significantly higher failure rates with HFNC (RR 7.78), whereas RCTs showed no significant difference (RR 1.11). There were no significant differences in endotracheal intubation rates (RR 0.75, 95% CI 0.51-1.09) or pediatric intensive care unit length of stay (MD -0.16 days, 95% CI -0.79 to 0.47) between the groups. HFNC demonstrated a trend toward fewer local adverse events, such as nasal/skin trauma (RR 0.30, 95% CI 0.06-1.52), than did NIV. The certainty of evidence according to GRADE was low for all outcomes. HFNC showed no significant differences from NIV in critical clinical endpoints, including intubation rates and intensive care duration. Differences in treatment failure rates appeared to be influenced by study design, highlighting potential confounding by indication in observational data. Given its improved tolerability and trend toward reduced mucosal trauma, HFNC may represent a viable first-line noninvasive intervention for pediatric bronchiolitis.

high-flow nasal cannulanon-invasive ventilationpediatric bronchiolitisacute respiratory failure
مراجعةوصول مفتوح2026

Clinical Value of Scapular-Targeted Rehabilitation Within the Rotator Cuff Care Continuum: A Systematic Review and Meta-analysis of Conservative and Postoperative Evidence

Orthopedic Reviews · مجلد 18 · 165083-165083

Background: Scapular-targeted rehabilitation is increasingly incorporated into the management of rotator cuff-related shoulder disorders; however, its clinical value across both conservative and postoperative stages of care remains uncertain. Objective: To evaluate the effectiveness of scapular-targeted rehabilitation on pain, disability, and shoulder function across the rotator cuff care continuum. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through May 2026. Eligible studies included adults with rotator cuff-related shoulder pain, subacromial pain syndrome, subacromial impingement syndrome, scapular dyskinesis-associated shoulder disorders, or patients undergoing rehabilitation following rotator cuff repair. Randomized controlled trials were included in quantitative synthesis. Random-effects models were used to pool standardized mean differences (SMDs) or mean differences (MDs) with 95% confidence intervals (CIs). Results: Nine studies met the inclusion criteria, comprising seven randomized controlled trials, one propensity score-matched study, and one single-group pre-post study. Meta-analysis demonstrated that scapular-targeted rehabilitation significantly reduced pain compared with control interventions (SMD -0.88, 95% CI -1.71 to -0.06; I²=84.8%) and significantly improved shoulder function measured by the Constant-Murley Score (MD 6.94, 95% CI 0.37 to 13.52; I²=85.7%). Disability outcomes favored scapular-targeted rehabilitation but did not reach statistical significance (SMD -0.47, 95% CI -1.05 to 0.11; I²=72.8%). Postoperative studies generally reported favorable effects on pain, function, and range of motion, although evidence was insufficient for quantitative synthesis. Conclusions: Scapular-targeted rehabilitation appears to be a useful adjunct within comprehensive rotator cuff rehabilitation, with evidence supporting improvements in pain and shoulder function. Evidence for disability reduction and postoperative effectiveness remains inconclusive, warranting further high-quality trials across the rotator cuff care continuum.

rotator cuff diseaserotator cuff repairshoulder impingement syndromesubacromial pain syndrome